Skip to main content
Netherlands News in English

Main navigation

  • Top stories
  • Health
  • Crime
  • Politics
  • Business
  • Tech
  • Culture
  • Sports
  • Weird
  • 1-1-2
Image
Vaccination
Vaccination - Credit: belchonock / DepositPhotos - License: DepositPhotos
Health
Coronavirus
Covid-19
SARS-CoV-2
vaccine
AstraZeneca
Oxfort University
Biontech
Pfizer
Ben van der Zeijst
Friday, 23 October 2020 - 12:40

Share this article:

Covid-19 vaccine early next year "realistic", Dutch expert says

It is "quite realistic" that there will be an effective vaccine against Covid-19 in early 2021, Ben van der Zeijst, former head of public health institute RIVM and emeritus professor of vaccines at Leiden University Medical Center, said to Nieuwsuur.

According to Van der Zeijst, at least two vaccines are doing well in their third phase of development - the vaccine being developed by Astra Zeneca and Oxford University, and the one being developed by Pfizer and Biontech. Pfizer hopes to know within two weeks whether their vaccine is effective.

These two vaccines are currently being tested on tens of thousands of people, in many cases in areas very affected by the virus. "So you can easily see if it helps," Van der Zeijst said. "If you add that to the hopeful earlier two phases of the studies, I am optimistic."

"We already know that the vaccines produce antibodies to protect us, even more than sick people produce," Van der Zeijst said "I think two vaccines will be approved by the end of this year. Then I hope that enough has already been produced and then we can start distributing."

The vaccines can only be submitted to the European Medicines Agency (EMA) for approval after the third and decisive phase of development has been completed. Given the severity of the pandemic, the Dutch branch of the EMA, medicines evaluation board CBG, decided to do a rolling review on the Covid-19 vaccines, in which each phase of the studies are submitted to the CBG as they finish, instead of only after the end of phase three.

"Given the severity of the pandemic, we are re doing our utmost, with more manpower. But that will not be at the expense of quality at any time," Ton de Boer of CBG said to Nieuwsuur. He does not want to speculate on when a vaccine will be ready. "We will only know more when the third phase is also in our hands for assessment. Until then, we cannot say anything about it."

More like this

Image
Vials of Covid-19 vaccines produced by Pfizer, Moderna and AstraZeneca. March 21, 2021
Dutch gov't did too little to prevent cronyism in buying Covid vaccines: Court of Audit
Image
A healthworker looking through a window in Hospital during the coronavirus pandemic.
Five years after first Covid-19 infection Netherlands is even less prepared for pandemic
Image
Vials of Covid-19 vaccines produced by Pfizer, Moderna and AstraZeneca. March 21, 2021
Unvaccinated were twice as likely to die from Covid as vaccinated: Nivel
Image
A hospital isolation room
Dutchman had coronavirus for 613 days; Virus mutated over 50 times in his body
Make NL Times your top Google source

Follow us:

Latest stories

  • Wasteful Oranje punished as Algeria snatch late victory in World Cup warm-up
  • Dutch State buys medieval ring found with metal detector for €83,150
  • Rotterdam shooting suspect arrested in Spain within days of fleeing
  • Nearly 90% of Dutch dermatologists link TikTok skincare trends to patient skin problems
  • Dogs falling ill, dying after swimming in the IJmeer near Amsterdam & Almere

Top stories

  • Court rules Ye can remain in Netherlands for Arnhem performances this week
  • New A'dam coalition planning parking +tourist tax hike, free public transport for kids
  • European Commission tells Netherlands to stop extra border controls
  • Pregnant woman thrown to ground at Zeist asylum shelter was trying to ask cop a question
  • Senior Dutch virologist, colleague accused of smuggling inactive Mpox into United States

© 2012-2026, NL Times, All rights reserved.

Footer menu

  • Change Privacy Settings
  • Privacy Policy
  • Contact
  • Partner Content